Radiopharmaceuticals are a rapidly growing area of oncology, fueled by advances in targeted therapies and expanding product pipelines. But bringing these therapies from development to commercialization presents unique manufacturing challenges, from isotope supply and specialized GMP facilities to the “just-in-time” distribution models required by the short half-lives of these radioactive medicines.
In this episode of Off Script, we spoke with Thijs Spoor, CEO of Perspective Therapeutics, about the current state of radiopharmaceutical manufacturing and what the industry needs to support the next phase of growth. Spoor discussed why manufacturing capacity has become one of the industry's biggest bottlenecks, how companies are approaching facility expansion and supply chain resilience, and why distributed manufacturing networks are integral. He also touched on workforce challenges, evolving regulatory expectations, and continued investment that is supporting the industry's growth.
Podden och tillhörande omslagsbild på den här sidan tillhör
Pharma Manufacturing. Innehållet i podden är skapat av Pharma Manufacturing och inte av,
eller tillsammans med, Poddtoppen.
